A look at three small biotechs that big drugmakers are drooling over. Source: BioSpace

The FDA's Breakthrough Therapy Designation for balovaptan was primarily based on efficacy findings in the VANILLA study, a Phase II trial of balovaptan in adults with ASD. Source: BioSpace

AbbVie provided an unexpectedly strong 2018 guidance revision, largely built on the new corporate tax rate. Source: BioSpace

the FDA has determined that it cannot approve the NDA in its present form and provides specific reasons for this action along with recommendations needed for resubmission. Source: BioSpace

Apostle, headquartered in Sunnyvale, Calif., hopes to file an IPO or establish other strong business collaborative routes in five years. Source: BioSpace

When the debt is repaid next week, Valeant will have reduced its debt by more than $6.7 billion since the end of the first quarter of 2016.. Source: BioSpace

Now insiders say J&J has decided it is no longer interested. Source: BioSpace

The company burned through $1.2B and never brought a drug to market in its 37 years. Source: BioSpace

Based in Toronto, Ontario, Fibrocor Therapeutics was launched in January 2017. Source: BioSpace

The drug is the first available FDA-approved Peptide Receptor Radionuclide Therapy. Source: BioSpace